Image

Prevention ICONA Dedicated Ensemble

Prevention ICONA Dedicated Ensemble

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Despite significant advances in HIV treatment, transmission remains a public health concern. In 2022, there were 1.3 million new HIV infections worldwide and 1,888 new diagnoses in Italy, with sexual transmission being the predominant route. Many individuals are still diagnosed late, and a portion of people living with HIV are unaware of their status. Pre-Exposure Prophylaxis (PrEP) has emerged as an effective biomedical strategy to prevent new infections, especially when integrated into comprehensive prevention efforts.

Study Objectives The primary objective of this observational study is to establish a large prospective cohort of individuals using PrEP in Italy. The study aims to assess PrEP's effectiveness, tolerability, adherence, and barriers to long-term use in a real-world setting. These data will be instrumental in guiding future strategic interventions to optimize PrEP management and move toward the goal of zero new HIV infections in Italy.

Primary Objective

  • To assess the incidence of new HIV infections among PrEP users in Italy. Secondary Objectives
  • Incidence of other sexually transmitted infections (STIs);
  • Tolerability of PrEP;
  • Psychological and behavioral aspects related to PrEP use;
  • Adherence and persistence in care;
  • Use of therapies and prophylaxis for STIs during PrEP use. Study Design and Coordination This is a prospective observational study, promoted by Fondazione ICONA in collaboration with clinical centers and community-based organizations. The coordinating enrolling center is INMI "L. Spallanzani" IRCCS in Rome.

Participating Centers:

  • 49 university and hospital-based centers across Italy;
  • 4 non-clinical checkpoints offering PrEP screening, prescription, and follow-up.

Study Population Adults (≥18 years) who are HIV-negative, sexually active, and considered eligible for PrEP per national or international guidelines, including both new and current PrEP users.

Inclusion Criteria

  • Age ≥18 years;
  • Negative HIV test at enrollment;
  • Willingness to initiate or continue PrEP;
  • Informed consent provided. Exclusion Criteria
  • HIV infection or strong suspicion of infection;
  • Contraindications to PrEP medications; Known allergy to PrEP components; Refusal to comply with study procedures.

Description

The PrIDE study is a national, multicenter, prospective observational cohort aimed at assessing the effectiveness and real-world implementation of HIV pre-exposure prophylaxis (PrEP) in Italy. It collects sociodemographic, clinical, laboratory, behavioral, and quality-of-life data from about 5,000 HIV-negative adults (≥18 years) initiating or already on PrEP, in accordance with Italian and international guidelines.

All 49 university and hospital infectious disease clinics and 4 community-based checkpoints across Italy can participate. Participants are followed every 3-5 months through routine clinical visits, including HIV/STI testing, safety labs, and electronic questionnaires via a dedicated mobile app.

The primary objective is to estimate the incidence of HIV seroconversion, while secondary aims include monitoring sexually transmitted infections, evaluating safety and tolerability, and analyzing adherence, persistence, and behavioral factors. Data are collected in a secure, encrypted eCRF managed by the ICONA Foundation.

The study is coordinated by the National Institute for Infectious Diseases "L. Spallanzani" IRCCS in Rome, will run for at least 10 years, and requires approval from the Ethics Committees of all participating centers.

Eligibility

Inclusion Criteria:

  • Age >18 years
  • Negative HIV Ab/Ag test (4th generation or higher) at the enrollment visit
  • Request and/or willingness to take PrEP, or already on PrEP
  • Ability to understand the study procedures and to sign informed consent

Exclusion Criteria:

  • Individuals with HIV infection or with strong clinical/epidemiological suspicion of HIV infection
  • Individuals with contraindications to the use of medications included in the PrEP regimen (as per the product information)
  • Documented allergy to one or more pharmacological components of the proposed PrEP regimen
  • Lack of willingness to adhere to the required procedures and follow-up assessments

Study details
    PrEP
    PrEP Adherence Monitoring
    HIV
    HIV -1 Infection
    STI
    STI Prevention

NCT07186244

Fondazione ICONA

16 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.